2-Arylimidazo[2,1-b]benzothiazoles: a new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer's brain

David Alagille; Herve DaCosta; Ronald M Baldwin; Gilles D Tamagnan

doi:10.1016/j.bmcl.2011.03.052

2-Arylimidazo[2,1-b]benzothiazoles: a new family of amyloid binding agents with potential for PET and SPECT imaging of Alzheimer's brain

Bioorg Med Chem Lett. 2011 May 15;21(10):2966-8. doi: 10.1016/j.bmcl.2011.03.052. Epub 2011 Mar 21.

Authors

David Alagille¹, Herve DaCosta, Ronald M Baldwin, Gilles D Tamagnan

Affiliation

¹ Institute for Neurodegenerative Disorders, 60 Temple St., Suite 8A, New Haven, CT 06510, USA. [email protected]

PMID: 21458990
DOI: 10.1016/j.bmcl.2011.03.052

Abstract

We designed and synthesized a small series of 2-aryl-imidazo[2,1-b]benzothiazole, representing a combination of motifs from the two most potent amyloid imaging agents, PIB and IMPY. The binding affinity of the new compounds ranged from 6 to 133 nM. Among the best compounds, 3b (K(i)=6 nM) can be labeled with (11)CH(3) for PET imaging whereas 3j (K(i)=10.9 nM) can be labeled with (123)I for SPECT imaging.

MeSH terms

Alzheimer Disease / diagnosis*
Amyloid* / chemistry
Amyloid* / metabolism
Benzothiazoles / chemical synthesis*
Benzothiazoles / chemistry
Binding, Competitive
Biological Assay
Humans
Imidazoles / chemical synthesis*
Imidazoles / chemistry
Positron-Emission Tomography
Protein Binding
Tomography, Emission-Computed, Single-Photon

Substances

Amyloid
Benzothiazoles
Imidazoles
benzothiazole